|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1953
|
|
gptkbp:ATCCode
|
P01BD01
|
|
gptkbp:brand
|
gptkb:Daraprim
|
|
gptkbp:CASNumber
|
58-14-0
|
|
gptkbp:chemicalFormula
|
C12H13ClN4
|
|
gptkbp:contraindication
|
megaloblastic anemia due to folate deficiency
|
|
gptkbp:drugClass
|
antiprotozoal
|
|
gptkbp:eliminationHalfLife
|
96 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:genericName
|
pyrimethamine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Daraprim
|
|
gptkbp:legalStatus
|
prescription only
Rx-only (US)
|
|
gptkbp:manufacturer
|
gptkb:Vyera_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
inhibits dihydrofolate reductase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notableEvent
|
price increase controversy in 2015
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
C (US)
|
|
gptkbp:prescribedWith
|
gptkb:leucovorin
sulfadiazine
|
|
gptkbp:prescriptionRequired
|
yes
|
|
gptkbp:priceIncreaseBy
|
gptkb:Martin_Shkreli
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
rash
|
|
gptkbp:usedFor
|
treatment of malaria
treatment of toxoplasmosis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Pyrimethamine
|
|
gptkbp:bfsLayer
|
6
|